Impact of Three Different Gonadotrophin Regimes on Egg Donation Program
NCT ID: NCT00829075
Last Updated: 2009-01-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
INTERVENTIONAL
2005-01-31
2006-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gonadotropin Type in Ovarian Stimulation
NCT02437032
Transfer of Fresh Versus Frozen/Thawed Embryos in IVF Cycles Where GnRH Agonist is Utilized for Oocyte Maturation.
NCT00365027
Ovarian Stimulation With FSH Alone Versus FSH Plus GnRH Antagonist in an Oocyte Donor/Recipient Programme
NCT05759871
Type of Gonadotropin and Embryo Kinetics of Development
NCT02402192
Growth Hormone (GH) in in Vitro Fertilization (IVF) Poor-responder Patients
NCT01298960
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
I
only r-FSH TREATMENT
r-FSH
II
only HP-hMG TREATMENT
HP-hMG
III
r-FSH plus HP-hMG TREATMENT
r-FSH plus HP-hMG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
r-FSH
HP-hMG
r-FSH plus HP-hMG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* regular menstrual cycles
* no family history of hereditary or chromosomal diseases
* normal karyotype
* BMI 18-29 Kg/m2
* negative screening for sexually transmitted diseases
Exclusion Criteria
18 Years
34 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto Valenciano de Infertilidad, IVI VALENCIA
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
IVI Valencia
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marco Melo, MDPhD
Role: PRINCIPAL_INVESTIGATOR
IVI Valencia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IVI Valencia
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VLC-MM-0501-37
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.